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Borderline ovarian tumors have an excellent prognosis. In stage I disease, no therapy in
addition to surgery is needed, and conservation ofovarian tissue for future childbearing may be
appropriate. In advanced stages, the useofadjuvant therapy has not consistently led tocures, and
complications have been reported. A randomized study of no adjuvant therapy versus adjuvant
treatment with long-term follow-up will be necessary to determine the efficacy of additional
treatment.
INTRODUCTION
In 1929, Taylor [1] described "semi-malignant" serous tumors of the ovary which,
although histologically aggressivewith implantsthroughout theperitoneal cavity, were
clinically benign. In fact, several patients had long-term survival even though they had
incomplete surgical excision ofthetumor from the peritoneal cavity. It was much later,
in 1961, that the International Federation of Gynecology and Obstetrics (FIGO)
recognized these proliferative tumors and in 1971 divided the common epithelial
ovarian cancers into three subgroups: benign, borderline, and malignant [2]. The
World Health Organization (WHO) accepted this histologic classification of ovarian
tumors into these categories in 1973 [3].
Later, Hart and Norris [4] gave guidelines for the concept of borderline ovarian
tumors ofmucinous subtype. These concepts were further clarified and later expanded
beyond the serous and mucinous tumors to include theother histologic types, including
endometrioid carcinoma, Brenner tumors, and clearcell carcinoma [5-1 1]. In general,
borderline tumors are characterized as neoplasms exhibiting cellular proliferative
changes greater than the benign form of the same type of tumor, but not showing
destructive invasion ofthe ovarian stroma.
More specifically, the serous neoplasms are generally characterized by the presence
of papillary serous excrescences with complex branching and epithelial tufting. The
papillary stalks can be lined by cells two or three layers thick that show mild to
moderate degrees ofatypia. Psammoma bodies are frequently found. Mitosis, necrosis,
and significant pleomorphism are absent.
In the mucinous tumors, there may be a variety of cystic and papillary structures
lined by tall columnar mucinous epithelium two or three cell layers thick. The cells
may show marked atypia with large hyperchromatic nuclei. Mitoses and invasion of
stroma are absent. There should be no desmoplastic response in the ovarian stroma
secondary to the glandular outpouching formation. Furthermore, it is important that
the pathologic finding ofglandular inclusion cysts lined by tubal or serous epithelium
in the omentum, peritoneum, or nodes be described as endosalpingiosis and not be
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considered as evidence of disease. This distinction is important not only at the initial
staging procedure but also at evaluation for persistent disease, such as at second-look
surgery.
The separation ofovarian neoplasms into malignant and borderline forms is crucial,
because the pathobiology and prognosis for these two entities are markedly different,
and particularly since borderline ovarian tumors account for between 9.2 percent and
16.3 percent ofall ovarian neoplasms [12-14].
This review ofthe English-language literature from 1979 to 1989 will concentrate on
thejustification for adjuvant treatment after surgery in borderline ovarian tumors. In
early-stage cancer (stage I), there areseveral studies which suggested that noadjuvant
therapy is needed and, in fact, conservation ofovarian tissue is acceptable. In the more
advanced stages, the question appears still to be open.
Statistical analysis of the differences in percentages was done, using either the
chi-square test or Fisher's exact test, where appropriate, and using .05 as the level of
significance.
AGE, GRAVITY, AND PREGNANCY
In general, patients with borderline ovarian tumors are younger than those with
invasive ovarian carcinoma; in the most recent FIGO reportof 1988, over 25 percentof
the patients with borderline ovarian tumors were under the age of 40, while, for
invasive ovarian tumors, less than 10 percent areunder this age [15]. In theGenadry et
al. [16] review of 154 patients, the range ofages was from 6 to 102, with a peakduring
the reproductive years. In Chambers et al. [17], the mean age was 44.1 years and the
median was 40.4 years, with a range of 15 to 85 years, and 47 percent were younger
than age 40.
Nulliparity, which may reflect the younger age of the patients, has been noted in a
number of studies; e.g., Chambers et al. [17] reported that 29 percent were
nulliparous, and Bostwick et al. [18], 43.1 percent. Genadry et al. [16] noted that 38
percent of their population with borderline ovarian cancer was nulliparous; however,
only 25 percent ofthe patients over age of20 were nulliparous. Finally, several reports
noted an association with pregnancy [16-19]. In Chambers et al. [17], four patients
were pregnant at the time of presentation, ofwhom two were recognized at Cesarean
section; however, these four patients constituted only 9 percent of the patients under
the age of 40. Genadry et al. [16] reported on 14 patients who were pregnant at the
time of initial diagnosis; they represented 9 percent of the total population and 15.9
percent of the patients younger than age 40. Several patients have also been found
during infertility evaluation [17,20]. It would appear that these associations are not
causal relationships but reflect the younger population in which this type of neoplasm
occurs.
Few studies comment on the racial background of the patients with borderline
ovarian tumors, but Genadry et al. [16] noted no racial difference from the general
population oftheir study.
SIGNS AND SYMPTOMS
Abdominal and/or pelvic pain has been recorded as a presenting symptom in 20
percent to 58 percent ofthe patients; following this, the most common complaint was
increasing abdominal girth in 40-43 percent of the patients [13,14,18,21-23]. Other
symptoms included increased urinary frequency, dyspareunia, abnormal vaginal
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TABLE I
Number of Patients with Borderline Ovarian Tumors According to F.I.G.O. Stage
Stage
First Author [Reference] (Year) I II III IV U
Fort [24] (1989) 29 5 11 1 2
Chambers [17] (1988) 73 9 12 0 0
Hopkins [21] (1987) 34 13 17 0 4
Yazigi [22] (1988) 31 5 0 0 0
Yoonessi [23] (1988) 22 1 3 0 0
Bostwick [18] (1986) 87 8 14 0 0
Kliman [25] (1986) 56 6 14 0 0
Nation [13] (1986) 53 4 7 1 0
Barnhill [26] (1985) 47 13 33 1 0
O'Quinn [27] (1985) 2 4 7 0 0
Tazelaar [28] (1985) 61 0 0 0 0
Creasman [29] (1982) 55 0 0 0 0
Genadry [16] (1981) 108 21 24 1 0
Minyi [30] (1980) 24 11 23 0 0
Nikrui [14] (1981) 44 6 5 1 6
Russell [31] (1979) 122 6 16 0 0
Katzenstein [7] (1978) 30 9 16 0 0
Total Number 878 121 202 5 12
% Staged Patients 72.8 10.0 16.7 0.4
U, Unstaged disease
bleeding, and cramping associated with bowel function [13,14,16,18,21-23]. There
remained, however, a significant number, as high as 30 percent of patients who were
asymptomatic, and the diagnosis of a pelvic mass was made on routine physical
examination [22]. It is clear that the presentation of the borderline ovarian tumor is
not unique. Many of the women are asymptomatic, and the neoplasm is found
incidentally either as an unexpected finding at surgery, e.g., at Cesarean section or on
routine pelvic examination.
STAGING
Table 1 summarizes 17 recent studies on borderline ovarian tumors which contain
information on the FIGO stages ofthe disease; these or subsets ofthese 1,218 patients
will form the basis of this review [7,13,14,16-18,21-31]. There were 1,206 patients
who were staged according to FIGO I-IV. As can be seen, the majority of patients
(72.8 percent) had stage I disease; this percentage drops dramatically to 10.0 percent
for stage II, 16.7 percent for stage III, and 0.4 percent for stage IV.
Yazigi et al. [22] reviewed the surgical staging, including peritoneal cytology,
omental sampling, biopsies of the diaphragm, extra-pelvic peritoneum, and pelvic and
periaortic lymph nodes in 29 patients with presumed early-stage borderline ovarian
neoplasms, stage I (25 cases), and stage II (4 cases). Fourteen patients had all
procedures, and the others had at least one of these. They found that 7 percent had
positive peritoneal cytology, 13 percent had microscopic omental metastases, 7 percent
had occult diaphragmatic metastases, and 33 percent had positive lymph nodes. That
is, of the 29 patients with presumed stage I or stage II disease, 7 (24 percent) were
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TABLE 2
Number of Patients with Histologic Subtypes of Borderline Ovarian Tumors
First
Author [Reference] Serous Mucinous Endometrioid Brenner Clear Cell Mixed
Fort [24] 32 14 1 1
Chambers [17] 61 33
Hopkins [211 51 11 3 - 3
Yazigi [22] 25 11
Yoonessi [23] 10 14 1 1
Bostwick [18] 73 30 6
Kliman [251 29 39 3 5
Nation [13] 28 36 I 1
Barnhill [26] 77 17
O'Quinn [27] 10 1 2
Tazelaar [28] 26 12 3
Nikrui [14] 36 25 1
Russell [31] 70 52 14 1 3 4
Total Number 528 295 25 2 3 23
%0 60.3 33.7 2.8 2.6
upstaged to stage III as a resultofthe staging procedures. Furthermore, although none
ofthe 25 patients with stage I disease was found to havehistologically confirmed occult
intraperitoneal spread, three of 13 patients who had retroperitoneal lymph nodes
sampled had metastases. On the other hand, 75 percent (three of four) of the stage II
patients had occult intra-abdominal extension of tumor; consequently, the spread of
disease needs to be histologically documented in order to stage the disease properly. It
is important that implants showing endosalpingiosis be properly interpreted.
HISTOLOGIC SUBTYPES
Summarizing the papers which did not restrict the histologic subtype, Table 2 shows
that there were 876 tumors characterized. The overwhelming histology was serous
(60.3 percent), followed by mucinous (33.7 percent). Endometrioid, Brenner, and clear
cell neoplasms accounted for only 30 histologies, while 2.6 percent were mixed
histologic subtypes. In general, mucinous neoplasms occurred at a lower stage; e.g., in
Chambers et al. [17], only 6.0 percent of these were stage III compared with 16.4
percent of the serous neoplasms were stage III. Others have reported no mucinous
tumors beyond stage I [18,32].
Bell and colleagues [33] in a review of 56 patients with serous borderline tumors
have identified four significant histologic characteristics ofthe tumor. In their review,
all patients had peritoneal implants and an evaluation was done ofthe invasiveness of
the metastatic lesion, the cytologic atypia, the mitotic index, and the residual disease
after primary surgery. The overall survival at five and ten years was 96 percent and 77
percent among these patients; however, among those with no high-risk factors there
were no deaths due to tumor. This result compares with the patients with one or more
of these characteristics where the ten-year survival rate was only 56 percent.
Furthermore, the most significant factor was the "invasive" implants. Among the 50
patients without this type of peritoneal spread, only three died of the disease; on the
other hand, four of the six patients with invasive implants died ofdisease. This report
raises the question as to whether or not in a high-risk group with "invasive" implants
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adjuvant treatments should be tried. In a report by Michael and Roth [34] of 13
patients, there was no difference in survival between the group with invasive implants
and those without these. McCaughey et al. [35] in another small series found that five
patients with invasive implants had progressive disease, compared with only two
patients of 13 without invasive implants. These discrepancies may reflect a difference
in the definition of the invasive peritoneal implants. The question of appropriate
treatment in a high-risk group, however, still has not been answered.
TUMOR MARKER, CA-125
The role of the serum tumor marker, CA-125, in borderline ovarian tumors has not
been defined as it has been in the management and detection of invasive ovarian
carcinoma. In several reports of small series of three or four patients, the serum
CA-125 levels have been noted to be elevated in patients with borderline ovarian
tumors [36-38]. The actual values were usually lower than those for invasive
neoplasms. In Chambers et al., there were only four of 18 patients with borderline
tumors in whom the serum CA-125 level was elevated. Interestingly, in one patient
treated originally with an ovarian cystectomy, a recurrence was found concomitantly
with a rise in the serum CA-125 level to 96 U/ml. This finding suggested a possible
role in the follow-up of patients with borderline ovarian tumors. Recently, Rice et al.
[39] reported in a review of borderline ovarian tumors that six of eight patients with
elevated serum CA-125 levels had greater than stage I disease, while all five patients
with stage I disease who had determination ofCA-125 had normal levels. The reported
number ofpatients with serum determinations of CA-125 is too small to generalize, if
elevated levels correlate with aggressive or recurrent borderline ovarian tumors.
STAGE I AND STAGEII TREATMENT
The mainstay of treatment for early ovarian carcinoma is surgery. Table 3
summarizes the initial treatment for stage I patients in 584 patients. In the literature,
there are few details concerning doses or schedules of chemotherapy agents or of
radiation. In the tables, chemotherapy includes both single- and multiple-agent
therapy and radiation includes not only external beam irradiation, either pelvic or
abdominal, but also intraperitoneal radioactive colloids of gold or phosphorus. Some
authors listed persistent and recurrent disease together. If stated separately in the
paper, persistent disease at second-look surgery was not stated as recurrence, unless so
noted. Note that 77.0 percent of the patients had no additional treatment and 13.7
percent received adjuvant chemotherapy.
There is only one prospective randomized study in the literature on the treatment of
borderine ovarian tumors. This study by Creasman et al. [29] addresses the problem of
adjuvant therapy in stage I borderline ovarian tumors. In this 1982 paper, 55 patients
with stages IA or IB disease were randomized after a minimum of a total abdominal
hysterectomy and bilateral salpingo-oophorectomy to either no further treatment (25
patients), pelvic irradiation of 5,000 rads over five to six weeks (13 patients), or
melphalan 0.2 mg/kg for five days every four weeks for 18 months(17 patients). There
was only one patient in a three-year follow-up who had a recurrence, and she died of
disease. This patient presented with a large tumor, measuring 34 cm, which ruptured
intraoperatively and was treated with radiation. Nine months after original surgery the
patient was found to have carcinomatosis and subsequently died. She may have been
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TABLE 3
Adjuvant Treatment for Stage 1 and Outcome
First Radiation Radiation Therapy
Author [Reference] No Therapy Chemotherapy Therapy and Chemotherapy
Fort [24] 15 11 3
Chambers [17] 56 15 2
Hopkins [21] 26 6 2
Yoonessi [23] 15 4 2 1
Bostwicka [18] 79 1 5 2
Kliman [25] 56
Nation [13] 42 5
Barnhill [26] 24 13 9 1
O'Quinn [27] 2
Tazelaar [28] 57 1 2 1
Creasman [29] 25 17 13
Nikrui [14] 36 4 4
Katzenstein [7] 19 1 7
Total Number 450 80 45 9
DOC 0 1 0 0
DOD 2 3b 1 0
Recurrence/Persistence 18 S' 2 1
% Death/Recurrence/Persistence 4.4 11.2 6.7 11.1
DOC, Dead ofcomplication
DOD, Dead ofdisease
'Recurrence/persistence listed together
bIncludes one death ofunknown cause
'All patients had positive second-look surgery.
understaged, in retrospect. This report concluded that surgery alone was as efficacious
as adjuvant treatment in these patients.
Other reports ofstage I disease address the conservative treatment ofthese patients.
Julian and Woodruff [40] showed that, in 25 patients with stage IA disease and
five-year follow-up, there was 100 percent survival with either unilateral oophorec-
tomy or hysterectomy and bilateral oophorectomy. Tazelaar et al. [28], in a seriesof61
patients with stage IA disease, compared 41 patients who were treated with a total
abdominal hysterectomy and bilateral salpingo-oophorectomy to 20 patients who were
treated with more limited surgery, including four with cystectomy and 16 with
unilateral adnexectomy. In the conservatively treated group, 15 percent had recur-
rence compared to 5 percent in the other group; however, on further analyses, all 61
patients remained alive with no clinical evidence of disease after the surgery for
recurrent disease, at a follow-up of36 to 244 months. Theconservatively treated group
tended to develop recurrent disease earlier than those in the other group; however, the
difference in relapse-free survival between the two groups was not statistically
significant. Since there were no recurrences of the mucinous tumors, there was a 23
percent recurrence rate in the serous neoplasms treated conservatively compared with
a 7 percent rate in the other group. In Chambers et al. [17], 27.4 percent (20 patients)
of the patients with stage I disease were treated with conservative operations; within
this group, three patients subsequently developed recurrent disease, two after an
ovarian cystectomy alone. These two recurrences came earlier than the other recur-
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rences in stage I disease, at 12 and 15 months after initial surgery, compared with
recurrences at 23, 34, and 47 months. Furthermore, one of these patients had an
invasive ovarian carcinoma at recurrence. It would appear that conservation ofovarian
tissue is justified with these low recurrence rates and general overall excellent
survival.
The next question is: how conservative can the operation be? Lim-Tan et al. [20]
reviewed a series of 33 patients with stage I disease treated with ovarian cystectomy.
Four patients (12 percent) developed persistent or recurrent disease in the ipsilateral or
contralateral ovary; ipsilateral persistence or recurrence occurred in 8 percent. If the
resection margin of the specimen was positive for a neoplasm or there was removal of
more than one cyst, then persistence or recurrence almost always occurred. All the
patients were alive without evidence ofdisease in follow-up at 3-18 years. In this study,
however, 60 percent of the patients underwent additional surgery (and some with total
abdominal hysterectomy and bilateral salpingo-oophorectomy) shortly after the initial
ovarian cystectomy. This study concluded that ovarian cystectomy was justified to
preserve fertility in young women provided that the full extent of the disease was
known. Although these authors do not favor a biopsy of a normal-appearing contra-
lateral ovary, because of the risk of adhesion formation and increased mechanical
infertility of approximately 14 percent [41], this reviewer thinks that the biopsy is
necessary in order to stage the disease accurately, since up to 5-10 percent of
normal-appearing ovaries will have microscopic disease [42]. Eight of the 16 patients
with stage I disease who were treated conservatively by Lim-Tan et al. [20] sub-
sequently had a normal pregnancy.
In general, although there is only one prospective randomized study on the
treatment ofstage I disease, it would appear that for those patients who have surgically
treated stage I disease, a unilateral adnexectomy is sufficient, with careful follow-up.
Ofthe group ofpatients in Table 3 who had no adjuvant therapy after surgery, at least
11 of the 18 recurrences were in a preserved ovary. From Table 3 it can be seen that of
the 450 patients who did receive adjuvant therapy, 20 patients (4.4 percent) either died
ofdisease or had recurrent or persistent disease. If this result is compared with the 134
patients who received various adjuvant treatments, there were 13 patients (9.7
percent) who had similar fates. Although, using chi-square analysis in these outcomes,
the difference was significant (chi-square = 4.411; p = 0.037), it must be remembered
that the criteria for additional therapy were not stated in the various papers and may
have included inadequate staging. Thus, the increased poor outcome in the treated
group may reflect other factors than the treatments.
Table 4 summarizes the data on 75 patients with stage II borderline tumors treated
with various post-operative modalities; 28 percent received no adjuvant treatment and
36 percent received chemotherapy. Using Fisher's exact test to analyze the outcome of
recurrence, persistence, and death between those receiving and those not receiving
adjuvant treatments, there was no difference in outcome (p = 0.244). Again, none of
these results is from a prospective randomized study. In this stage of the disease, the
surgery should be a total abdominal hysterectomy and bilateral salpingo-oophorecto-
my, along with appropriate sampling of the peritoneal cavity.
In these early stages ofdisease, the question ofthe spillage oftumor from a ruptured
neoplasm is noted by several authors. Hopkins et al. [21] reported on seven such
patients with early disease who did not have recurrence in the peritoneum; six of these
patients received no adjuvant therapy. Tasker and Langley [19] had operative spillage
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TABLE 4
Adjuvant Treatment for Stage II and Outcome
First Radiation Radiation Therapy
Author [Reference] No Therapy Chemotherapy Therapy and Chemotherapy
Fort [24] 4 1
Chambers [17] 1 7 1
Hopkins [21] 5 1 4 3
Yoonessi [23] 1
Bostwick [18] 6 1 1
Kliman [25] 3 2 1
Nation [13] 2 2
Barnhill [26] 1 4 5 3
O'Quinn [27] 4
Nikrui [14] 2 3 1
Katzenstein [7] 1 - 2 3
Total Number 21 27 16 11
DOC - 1 1
DOD 1 2
Recurrence/Persistence 2 4a 2
% Death/Recurrence/Persistence 9.5 18.5 6.2 45.4
DOC, Dead ofcomplication
DOD, Dead ofdisease
'All patients had positive second-look surgery.
in 12 patients, and this event did not adversely affect the outcome. In the review ofthe
literature by Yoonessi et al. [23], they note reports on 15 patients with ovarian tumor
rupture, noneofwhom had recurrenceordied ofdisease. On theother hand, they noted
that ascites or positive peritoneal cytology was a bad prognostic factor with four of 14
patients dying from the disease.
STAGE III AND STAGE IV TREATMENT
The patients who raise the most controversy about additional treatment are those
who have intra-abdominal, retroperitoneal, or distant spread ofthe disease. Although
this condition represented approximately 17.2 percent of the patients with borderline
ovarian tumors, few details of the treatment with outcome were available. Of the
papers cited, there were only 139 patients with stage III borderline ovarian tumors
discussed. In Table 5, it can be seen that 51.7 percent ofthe patients were treated with
adjuvant chemotherapy (both alkylating agents and/or various combination chemo-
therapy regimens, sometimes including cis-platinum), 23.0 percent with radiation
(external beam irradiation or intraperitoneal radioactive colloids), and 15.1 percent
with a combination of radiation and chemotherapy. Only 14 (10.0 percent) patients
received no treatment in addition to the surgery.
An important issue, however, in trying to decide what effect additional treatment
had, is knowing the details of the initial surgery; unfortunately, these were not often
discussed. In some cases, the patients had only an exploratory laparotomy and biopsy
of the tumor, while in other series aggressively debulking surgery was performed.
Tasker and Langley [19], in 20 patients with extraovarian spread ofthedisease (fiveof
whom died of disease), noted no influence of residual disease on the outcome for
patients treated with various modalities. On the other hand, Bostwick et al. [18] noted
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TABLE 5
Adjuvant Treatment for Stage III and Outcome
First Radiation Radiation Therapy
Author [Reference] NoTherapy Chemotherapy Therapy and Chemotherapy
Fort [24] - 10 1
Chambers [17] 1 11
Hopkinsa [21] 5 5 4 3
Yoonessi [23] 1 2
Bostwickb [18] 2 1 2 9
Kliman [25] 5 9
Nation [13] 1 6
Barnhill [26] - 18 13 2
O'Quinn [27] 7
Nikrui [14] 4 1
Katzensteinc [7] 1 12 3
Total Number 14 72 32 21
DOC 0 2 0 0
DOD 1 13 2 2
Recurrence/Persistence 6 15d 8 11
% Death/Recurrence/Persistence 50.0 41.7 31.2 61.9
DOC, Dead ofcomplication
DOD, Dead ofdisease
'Five recurrences; died but listed as recurrences/persistence
bRecurrences and persistence listed together
cDeath and recurrence listed together (six ofseven died) included in recurrence/persistence
dFour patients had positive second-look surgery.
that the two patients with stage III disease who died had incomplete excision of the
neoplasm at initial surgery. Kliman et al. [25] reported on five patients with residual
tumor after surgery who did not receive post-operative treatment; four were alive and
well from 5.5 to 19 years after diagnosis.
Table 5 shows that the percentage of recurrences and deaths was highest in the
groups ofpatients whohad noadditional therapy (50percent) orwho weretreated with
radiation plus chemotherapy (61.9 percent). Further analyses, again using chi-square
to compare the outcome ofthe group ofpatients not receiving adjuvant therapy to the
patients receiving adjuvant therapy (chi-square = 0.6756; p = 0.794), showed the
difference was not significant. Moreover, deaths fromcomplications oftreatment must
be stressed in a disease which in general has an overall good survival. There were
reports of patients developing leukemia and even dying from leukemia secondary to
prolonged use of alkylating agents, a death due to cardiomyopathy after receiving
doxorubicin, and a death secondary to septicemia associated with neutropenia due to
treatment [14,17,19,21,24,27].
The number of patients treated for stage IV disease was too few to analyze and is
summarized in Table 6.
SECOND-LOOK SURGERY
In general, in the more recent studies, if adjuvant treatment was employed, it was
usually chemotherapy, although Hopkins et al. [21] reported greater use of radiation
with or without chemotherapy. Most papers do not specify thedetails ofdrugs or doses
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TABLE 6
Adjuvant Treatment for Stage IV and Outcome
First Radiation Therapy
Author [Reference] Chemotherapy and Chemotherapy
Fort [24] 1
Nation [13] 1
Barnhill [26] 1
Nikrui [14] 1
Dead ofDisease 2
of single agents or combination chemotherapy; furthermore, only few report the
efficacy of chemotherapy by documenting histologic response at second-look surgery.
Table 7 summarizes this literature. In the ten papers listed, 96 patients had
second-look surgery, usually after chemotherapy, but a few following observation
alone, or radiation either externally or as intraperitoneal colloids. In the stage I
patients, 27.3 percent had positive second-look procedures; in stages II-IV, 41.3
percent ofthe cases were positive.
The most detailed information is given by O'Quinn and Hannigan [27], who
reported on 13 patients (two with stage I, four with stage II, and seven with stage III)
who were treated with melphalan (0.2 mg/kg x five days) every four weeks for 12
courses. Ten patients subsequently underwent second-look surgery, and all patients
were found to begrossly and histologically positive for recurrent disease. Ofthis group,
five patients subsequently continued to take melphalan for 12 additional courses, and,
at third-look surgery, all patients were histologically positive for disease. No other
study consistently treated all the patients.
Nation and Krepart [13] reported on ten patients (five with stage I, one with stage
II, and four with stage III), treated with either melphalan orcis-platinum combination
chemotherapy, who had second-look surgery. They observed that none of the patients
with microscopic disease at the end of the initial surgery had a negative second-look
TABLE 7
Status of Second-Look Surgery for Borderline Ovarian Tumors
Stage I Stages Il-IV
First
Author [Reference] Positive Negative Positive Negative
Fort [24] 1 9 2 12
Chambers [17] 1 3 1 5
Yoonessi [23] 1 0
Bostwick [18] 0 4 3 11
Kliman [25] - 5 0
Nation [13] 2 3 3 2
Barnhill [26] 1 0 4 5
O'Quinn [27] 2 0 8 0
Tazelaar [28] 1 5
Nikrui [14] 0 0 0 2
Total Number 9 24 26 37
% Positive 27.3 41.3
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laparotomy; five patients had persistent disease. Barnhill et al. [26] reported on ten
patients (one with stage I, eight with stage III disease, and one with stage IV disease);
five patients had positive histologic findings at surgery. Of the five patients who
initially had microscopic disease, only one had a negative second look.
On the other hand, in the report by Chambers et al. [17], ten-patients (four with
stage I, two with stage II, and four with stage III) underwent second-look surgery, and
two had evidence of disease; one had been treated with melphalan and the other with
cis-platinum. Of the four patients with microscopic disease at the end of the primary
surgery, only one had a positive second-look surgery.
Kliman et al. [25] reported on five patients with residual but non-measurable stage
III disease, treated post-operatively with combination chemotherapy; all had positive
second-look surgery. They reported an overall response rate of 9.1 percent to
chemotherapy, and it was a partial response. It would appear from several reports,
although not all, that even microscopicdisease at the end ofthe initial surgery predicts
a positive second-look surgery.
In the report of Fort et al. [24], no patient with negative second-look surgery had a
recurrence, but the follow-up was short; furthermore, of the 24 staged patients who
underwent second-look surgery, three were positive, and two of these patients died of
disease.
Yoonessi et al. [23] reported negative second-look surgery after a combination of
doxorubicin, cis-platinum, cyclophosphamide, 5-fluorouracil, and methotrexate,
although details ofhistology and the number ofpatients treated were not given.
Hence, the only detailed report on second-look surgery, by O'Quinn and Hannigan
[27], clearly showed that melphalan did not eliminate borderline ovarian tumors.
Often many reports do not even give the agents used. On further analyses, the status of
second-look surgery does not depend on the stage ofthe disease. The rate ofpositivity
of second-look surgery for stage I disease was not statistically different than that for
the combined stages II-IV, comparing this outcome using chi-square analysis (chi-
square = 1.277; p = 0.258). It may be that borderline ovarian tumors are indolent in
their growth, and cytotoxic agents, which generally affect rapidly progressing tumors,
are ineffective.
SURVIVAL
The prolonged survival of patients with borderline ovarian tumors has been known
and thus the importance of long-term follow-up is necessary. In addition, recurrences
may manifest many years later. From Table 8, it can be seen that survival for stage I
disease at five years has been reported to range from 80 percent to 100 percent, and
even stage III has survival ranging from 64 percent to 96 percent. Long-term
follow-ups as reported by Nikrui [14] and Minyi [30] showed that, even at 15 years,
there was good survival. Aure et al. [12], in 1971, in a review of 161 patients with at
least five years' follow-up, noted a steady decline in the survival ofthese patients, with
a predicted 20-year mortality of at least 15-25 percent due to borderline ovarian
tumors. Minyi et al. [30] in 1980 reported on 58 patients with borderline ovarian
malignancy, with 63.8 percent of the patients treated post-operatively with adjuvant
radiation or chemotherapy; of these, 51 patients had long-term follow-up; there were
18 recurrences in 14 cases documented. Only four recurrences happened within two
years of the initial surgery, and 14 occurred more than five years later. The longest
interval before recurrence was 27 years after the initial surgery. This report
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TABLE 8
Survival of Borderline Ovarian Tumor by Stage and Histology
% Survival
First Author
Stage [Reference] 5 Years 10 Years 15 Years
I Kliman' [25] 100 92
Minyi' [30] 100 96 96
Russell' [311 92
III Klimana [25] 100
Minyia [30] 81 81 81
Russell [31] 75
I-II Hopkinsa [21] 100 100
Barnhill [26] 97
III Hopkins [21] 82 60
Klimana [25] 70
Barnhill [26] 88
Minyia [30] 96 85 80
Russell' [31] 64
I-III Chambers [17] 83
Barnhill [26] 95 87
Minyi' [30] 94 88 86
Russell' [31] 83
I-III (Mucinous) Bostwick' [18] 100 100
Barnhill [26] 78
1-111 (Serous) Bostwick' [18) 84 81
Barnhill [26] 97
Nikrui [14] 91 83 73
I-IV (Mucinous) Nikrui [14] 80 73 57
'Estimated survival from the graphs in the paper
underscores the fact that recurrences can occur late and, in fact, 77.7 percent of the
recurrences in this series took place more than five years after the initial surgery. In
addition, there is a report of prolonged quiescent and later spontaneous regression of
borderline tumors in a 26-year-old woman who underwent a bilateral oophorectomy
two and a half years after initial diagnosis; then, still untreated, had metastases
resected over seven years later and was doing well more than 20 years later [43]. In
Chambers et al. [17], analysis showed no difference in the survival rates between
patients who received adjuvant therapy compared to those treated with surgery alone.
This result held true not only for all stages, but also for stage I alone. Table 9 contains
this information on survival and status ofadjuvant therapy, In an unpublished update
of 140 patients with borderline ovarian tumors treated at Yale University, the overall
five-year survival was 90 percent, and comparing treated patients (48 patients) and
observed patients (92 patients), there was no difference in outcome. In some series,
serous tumors had a better prognosis, even though these tumors usually occurred at a
higher stage.
CONCLUSION
From this review of the literature, it is clear that the question of whether or not
adjuvant treatment is necessary for borderline ovarian tumors has not been completely
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TABLE 9
Survival of Borderline Ovarian Tumor by Adjuvant Therapy
First Author % Five-Year
Stage [Reference] Adjuvant Treatment Survival
I Chambers [171 No 85.0
Yes 80.0
I-III Chambers [17] No 84.6
Yes 76.5
I-III Barnhill [26] No 100
Yes (Chemotherapy) 91.0
Yes (Radiation) 95.0
settled. This conclusion results from the lack of prospective randomized studies for
various treatment regimens for borderline ovarian tumors. The decision to treat some
patients and not other patients with the same stage of disease may have been
influenced by inadequate staging in some patients or even residual disease in some;
these details are not stated in the various reports. In stage I, it appears clear that
surgical removal of the tumor is all that is necessary, provided that careful staging is
done in order to document the full extent of the disease. Once the woman has
completed her family, most authors favor removal ofthe other ovary, as it is at risk for
subsequent development of recurrence of a borderline ovarian tumor or even
carcinoma, as reported in a few cases [17,24,30]. There is a debateon whether or not in
a young patient, presenting with unilateral disease, a biopsy ofthe other ovary should
be done, because ofthe increased riskofinfertility. This reviewer feels that the disease
should be accurately staged and that the other ovary should be biopsied. In the more
advanced stages of disease, i.e., stages II-IV, the question of need for adjuvant
treatment certainly cannot be answered from the existing literature. It is clear,
however, that survival cannot beshown to have been improved with any treatment. It is
also important to note that patients have died from complications of therapy. In a
disease which has a relatively low mortality rate, this factor must be taken into
consideration. Clearly, a prospective randomized study with long follow-up is needed if
thequestion ofneed foradjuvant therapy is to becritically answered. From the current
literature available, this author favors surgical staging, aggressive surgical debulking
of the tumor, and careful observation of the patient. If there is recurrent disease,
surgery should be undertaken with the aim ofremoving the tumor.
The Gynecologic Oncology Group (GOG) has initiated a protocol in borderline
ovarian tumors to study the natural history and to assess the role of melphalan, with
secondary treatment with cis-platinum, in patients who haveprogressivedisease. In the
most recent update (1989), the date from this protocol were too early to analyze.
Clearly, because of the rarity ofthe tumor, it will be necessary to have a multi-center
study in order to answer the question of the appropriate treatment, if any, for a
borderline malignant ovarian tumor.
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